Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Revenue Recognition (Tables)

v3.10.0.1
Revenue Recognition (Tables)
12 Months Ended
Dec. 31, 2018
Revenue from Contract with Customer [Abstract]  
Contract with Customer, Asset and Liability
The following table summarizes the values of contract assets, capitalized commissions and contract liabilities as of December 31, 2018 and December 31, 2017 (in thousands):

December 31, 2018 December 31, 2017
(as adjusted) 
Current pharma contract asset  $ 86  $ 541 
Long-term pharma contract asset  268  31 
Total pharma contract asset  $ 354  $ 572 
Current pharma capitalized commissions  $ 271  $ 371 
Long-term pharma capitalized commissions  650  171 
Total pharma capitalized commissions  $ 921  $ 542 
Current pharma contract liability  $ 927  $ 1,406 
Long-term pharma contract liability  1,652  283 
Total pharma contract liability  $ 2,579  $ 1,689 
Disaggregation of Revenue
The following table details the disaggregation of revenue for both the Clinical and Pharma Services Segments (in thousands):

December 31, 2018 December 31, 2017
(as adjusted) 
December 31, 2016
(as adjusted) 
Clinical Services: 
Client direct billing  $ 164,888  $ 147,726  $ 126,288 
Commercial Insurance  40,360  35,473  52,801 
Medicare and Medicaid  35,566  29,493  30,517 
Self-Pay  1,059  405  553 
Total Clinical Services  241,873  213,097  210,159 
Pharma Services:  34,868  27,154  21,649 
Total Revenue  $ 276,741  $ 240,251  $ 231,808